Calidum’s products are based on a novel concept of receptor-targeted and DNA co-targeted [RTDT] delivery of radiation directly to DNA of a cancer cell. Calidum’s technologies have several unrivaled characteristics:
- are diagnostic as well as therapeutic
- allow concomitant detection of tumors and assessment of their aggressiveness
- can help distinguish indolent from progressive disease
- are radiotoxic only to cells that express the targeted receptor and make DNA when RTDT is present
- kill multidrug resistant and radioresistant cancer cells
- are non-immunogenic allowing repeated dosing
- are administered at extremely low doses of nanograms per kg body weight guaranteeing minimal pharmacologic toxicities
- can be used as adjuvants without increasing overall toxicity of the primary treatment
- have the lock-in-mechanism that traps RTDT in targeted cancer cells
- are compatible with the individualized treatment strategy that uses diagnostic imaging to identify cancer patients that may benefit from molecular radiotherapy
- FDA-approved IND application available for testing in the context of prostate cancer.
